一分钟看懂
这是一项关于晚期实体瘤的I 期研究，登记的药物或干预包括CAR-Tumor05；CAR-Tumor 05；CAR-Tumor M01，当前状态为尚未开始招募。登记地点显示中国北京有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
CAR-Tumor05；CAR-Tumor 05；CAR-Tumor M01 · I 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Cancer Hospital Chinese Academy of Medical Sciences 17 Panjiayuan Nanli, Chaoyang District · 北京
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- 1. Voluntarily sign the informed consent form, understand the study, agree to comply with the protocol, and agree to complete all trial procedures;
- 2. Be aged 18 years or over at the time of signing the informed consent form; gender is not restricted.
- 3. Patients with advanced solid tumours confirmed by histological and/or cytological examination of the primary and/or metastatic lesions.
- 4. Patients who have failed standard treatment, are at the end of standard treatment options, or are unsuitable for standard treatment for medical reasons.
- 5. Participants with an ECOG performance status score of 0-2 and an expected survival of at least 12 weeks.
- 6. Adequate organ and haematopoietic function: absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; platelet count ≥ 75 × 10⁹/L (no platelet transfusions or thrombopoietin (TPO) therapy within 2 weeks prior to the first dose); haemoglobin ≥ 90 g/L (no blood transfusions within 2 weeks); Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or endogenous creatinine clearance (CCr) ≥ 50 mL/min; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN; in patients with liver metastases, AST and ALT \< 5 × ULN; total serum bilirubin (TBIL) ≤ 2 × ULN; International Normalised Ratio (INR) ≤ 1.5 × ULN, or activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;
- 7. Women of childbearing potential must undergo a pregnancy test within 7 days prior to the start of treatment, with a negative result.
- 8. Male and female subjects of childbearing potential must agree to use reliable contraception during the trial and for at least 6 months following the last dose.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07859462；登记信息更新于 2026-10-05；本站同步于 2026-10-08。